TY - JOUR
T1 - Designed peptides as nanomolar cross-amyloid inhibitors acting via supramolecular nanofiber co-assembly
AU - Taş, Karin
AU - Volta, Beatrice Dalla
AU - Lindner, Christina
AU - El Bounkari, Omar
AU - Hille, Kathleen
AU - Tian, Yuan
AU - Puig-Bosch, Xènia
AU - Ballmann, Markus
AU - Hornung, Simon
AU - Ortner, Martin
AU - Prem, Sophia
AU - Meier, Laura
AU - Rammes, Gerhard
AU - Haslbeck, Martin
AU - Weber, Christian
AU - Megens, Remco T A
AU - Bernhagen, Jürgen
AU - Kapurniotu, Aphrodite
N1 - © 2022. The Author(s).
PY - 2022/8/25
Y1 - 2022/8/25
N2 - Amyloid self-assembly is linked to numerous devastating cell-degenerative diseases. However, designing inhibitors of this pathogenic process remains a major challenge. Cross-interactions between amyloid-β peptide (Aβ) and islet amyloid polypeptide (IAPP), key polypeptides of Alzheimer's disease (AD) and type 2 diabetes (T2D), have been suggested to link AD with T2D pathogenesis. Here, we show that constrained peptides designed to mimic the Aβ amyloid core (ACMs) are nanomolar cross-amyloid inhibitors of both IAPP and Aβ42 and effectively suppress reciprocal cross-seeding. Remarkably, ACMs act by co-assembling with IAPP or Aβ42 into amyloid fibril-resembling but non-toxic nanofibers and their highly ordered superstructures. Co-assembled nanofibers exhibit various potentially beneficial features including thermolability, proteolytic degradability, and effective cellular clearance which are reminiscent of labile/reversible functional amyloids. ACMs are thus promising leads for potent anti-amyloid drugs in both T2D and AD while the supramolecular nanofiber co-assemblies should inform the design of novel functional (hetero-)amyloid-based nanomaterials for biomedical/biotechnological applications.
AB - Amyloid self-assembly is linked to numerous devastating cell-degenerative diseases. However, designing inhibitors of this pathogenic process remains a major challenge. Cross-interactions between amyloid-β peptide (Aβ) and islet amyloid polypeptide (IAPP), key polypeptides of Alzheimer's disease (AD) and type 2 diabetes (T2D), have been suggested to link AD with T2D pathogenesis. Here, we show that constrained peptides designed to mimic the Aβ amyloid core (ACMs) are nanomolar cross-amyloid inhibitors of both IAPP and Aβ42 and effectively suppress reciprocal cross-seeding. Remarkably, ACMs act by co-assembling with IAPP or Aβ42 into amyloid fibril-resembling but non-toxic nanofibers and their highly ordered superstructures. Co-assembled nanofibers exhibit various potentially beneficial features including thermolability, proteolytic degradability, and effective cellular clearance which are reminiscent of labile/reversible functional amyloids. ACMs are thus promising leads for potent anti-amyloid drugs in both T2D and AD while the supramolecular nanofiber co-assemblies should inform the design of novel functional (hetero-)amyloid-based nanomaterials for biomedical/biotechnological applications.
KW - Alzheimer Disease/drug therapy
KW - Amyloid/pharmacology
KW - Amyloid beta-Peptides/chemistry
KW - Amyloidogenic Proteins
KW - Amyloidosis
KW - Diabetes Mellitus, Type 2/drug therapy
KW - Humans
KW - Islet Amyloid Polypeptide/chemistry
KW - Nanofibers
U2 - 10.1038/s41467-022-32688-0
DO - 10.1038/s41467-022-32688-0
M3 - Article
C2 - 36008417
SN - 2041-1723
VL - 13
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 5004
ER -